GI Cancers
August 2015
This bulletin covers aspects of esophageal, gastric, intestinal and colorectal cancers and should be
of interest to multidisciplinary teams working in this area.
Sections can include:
 Combined Modality Therapies
 Drug and Targeted Therapies
 Pathology, Staging, Polymorphisms & Biomarkers
 Prognosis, Survival & Risk Factors
 Radiotherapy & Imaging
 Supportive Care & Symptom Management
 Surgery
Many of the following articles are available online via the NHS Scotland Knowledge Network.
Please use the links where provided and your ATHENS password. A complete list of
available online journals and registration for ATHENS can be found at
www.knowledge.scot.nhs.uk/
If the article you require is not available via the NHS Scotland Knowledge Network and you
would like to request a print copy, please submit your request online at
www.quest.scot.nhs.uk
This bulletin contains a selection of material gathered from a search of the evidence base, and is
not intended to be comprehensive. Professional judgment should be exercised when appraising
the material. The Library takes no responsibility for the wording, content and accuracy of the
information supplied, which has been extracted in good faith from reputable sources. NHSGGC is
not responsible for the content of external internet sites.
Compiled by:
Kirsty Coltart
Subject Librarian
Beatson West of Scotland Cancer Centre
0141 301 7285, kirsty.coltart@ggc.scot.nhs.uk
General
Cohen DJ and Leichman L. (2015). Controversies in the treatment of local and locally
advanced gastric and esophageal cancers. Journal of Clinical Oncology 33,16:1754-1759.
Fakih, M.G. (2015). Metastatic colorectal cancer: current state and future directions.
Journal of Clinical Oncology 33,16:1809-1824.
Shah, M.A. (2015). Update on metastatic gastric and esophageal cancers. Journal of
Clinical Oncology 33,16:1760-1769.
Smith JJ and Garcia-Aguilar J. (2015). Advances and challenges in treatment of locally
advanced rectal cancer. Journal of Clinical Oncology 33,16:1797-1808.
Tamas K, Walenkamp AM, de Vries EG, et al. (2015). Rectal and colon cancer: Not just a
different anatomic site. Cancer treatment reviews 41,8:671-679.
Combined Modality Therapies
Bujko K, Glimelius B, Valentini V, et al. (2015). Postoperative chemotherapy in patients with
rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of
randomized trials comparing surgery +/- a fluoropyrimidine and surgery + a
fluoropyrimidine +/- oxaliplatin. European Journal of Surgical Oncology 41,6:713-723.
Chadi SA, Berho M and Wexner SD. (2015). Surgeon perspectives on the use and effects of
neoadjuvant chemoradiation in the treatment of rectal cancer: a comprehensive review of
the literature. Langenbecks Archives of Surgery 400,6:661-673.
Delbaldo C, Ychou M, Zawadi A, et al. (2015). Postoperative irinotecan in resected stage IIIII rectal cancer: final analysis of the French R98 Intergroup trial+. Annals of Oncology
26,6:1208-1215.
Garcia-Aguilar J, Chow OS, Smith DD, et al. (2015). Effect of adding mFOLFOX6 after
neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2
trial. Lancet Oncology 16,8:957-966.
Gerard JP, Chamorey E, Gourgou-Bourgade S, et al. (2015). Clinical complete response
(cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer.
Findings from the ACCORD 12/PRODIGE 2 randomized trial. Radiotherapy & Oncology
115,2:246-252.
Hong TS, Moughan J, Garofalo MC, et al. (2015). NRG Oncology Radiation Therapy
Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using
Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin
for Patients With Locally Advanced Rectal Cancer. International journal of radiation
oncology, biology, physics 93,1:29-36.
Kidane B, Coughlin S, Vogt K, et al. (2015). Preoperative chemotherapy for resectable
thoracic esophageal cancer. Cochrane Database of Systematic Reviews 5,001556.
Landry JC, Feng Y, Prabhu RS, et al. (2015). Phase II Trial of Preoperative Radiation With
Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and
Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in
Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN
Cancer Research Group E3204. Oncologist 20,6:615-616.
2
GI Cancers, August 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Moehler M, Baltin CT, Ebert M, et al. (2015). International comparison of the German
evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and
locally advanced gastric cancer, including adenocarcinoma of the lower esophagus.
Gastric Cancer 18,3:550-563.
NICE. IPG531 Preoperative high dose rate brachytherapy for rectal cancer. August 2015
Probst CP, Becerra AZ, Aquina CT, et al. (2015). Extended Intervals after Neoadjuvant
Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and
Potential Organ Preservation. Journal of the American College of Surgeons 221,2:430-440.
Quero L, Guillerm S and Hennequin C. (2015). Neoadjuvant or adjuvant therapy for gastric
cancer. World Journal of Gastrointestinal Oncology 7,8:102-110.
Rodel C, Graeven U, Fietkau R, et al. (2015). Oxaliplatin added to fluorouracil-based
preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced
rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, openlabel, randomised, phase 3 trial. Lancet Oncology 16,8:979-989.
Schulz C, Kullmann F, Kunzmann V, et al. (2015). NeoFLOT: Multicenter phase II study of
perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal
junction or gastric adenocarcinoma-Very good response predominantly in patients with
intestinal type tumors. International Journal of Cancer 137,3:678-685.
Servagi-Vernat S, Crehange G, Roullet B, et al. (2015). Phase II Study of a Platinum-Based
Adapted Chemotherapy Regimen Combined with Radiotherapy in Patients 75 Years and
Older with Esophageal Cancer. Drugs & aging 32,6:487-493.
Vincent J, Mariette C, Pezet D, et al. (2015). Early surgery for failure after chemoradiation in
operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD
9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone.
European journal of cancer 51,13:1683-1693.
Wilke TJ, Bhirud AR and Lin C. (2015). A Review of the Impact of Preoperative
Chemoradiotherapy on Outcome and Postoperative Complications in Esophageal Cancer
Patients. American Journal of Clinical Oncology 38,4:415-421.
Zhao Y, Dai Z, Min W, et al. (2015). Perioperative versus Preoperative Chemotherapy with
Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus: A Phase III
Randomized Trial. Journal of Thoracic Oncology: Official Publication of the International
Association for the Study of Lung Cancer 10,9:1349-1356.
Drug & Targeted Therapies
Aprile G, Ongaro E, Del Re M, et al. (2015). Angiogenic inhibitors in gastric cancers and
gastroesophageal junction carcinomas: A critical insight. Critical Reviews in OncologyHematology 95,2:165-178.
Argiles G, Saunders MP, Rivera F, et al. (2015). Regorafenib plus modified FOLFOX6 as
first-line treatment of metastatic colorectal cancer: A phase II trial. European journal of
cancer 51,8:942-949.
Blay JY, Shen L, Kang YK, et al. (2015). Nilotinib versus imatinib as first-line therapy for
patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a
randomised phase 3 trial. Lancet Oncology 16,5:550-560.
3
GI Cancers, August 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Braam HJ, Schellens JH, Boot H, et al. (2015). Selection of chemotherapy for hyperthermic
intraperitoneal use in gastric cancer. Critical Reviews in Oncology-Hematology 95,3:282-296.
Ciliberto D, Staropoli N, Caglioti F, et al. (2015). A systematic review and meta-analysis of
randomized trials on the role of targeted therapy in the management of advanced gastric
cancer: Evidence does not translate?. Cancer Biology & Therapy 16,8:1148-1159.
Cremolini C, Loupakis F, Antoniotti C, et al. (2015). Early tumor shrinkage and depth of
response predict long-term outcome in metastatic colorectal cancer patients treated with
first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the
Gruppo Oncologico del Nord Ovest. Annals of Oncology 26,6:1188-1194.
Dienstmann R, Salazar R and Tabernero J. (2015). Personalizing colon cancer adjuvant
therapy: selecting optimal treatments for individual patients. Journal of Clinical Oncology
33,16:1787-1796.
Ding HH, Wu WD, Jiang T, et al. (2015). Meta-analysis comparing the safety and efficacy of
metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI)
and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI). Tumour Biology 36,5:3361-3369.
Do K, Cao L, Kang Z, et al. (2015). A Phase II Study of Sorafenib Combined With
Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. Clinical
Colorectal Cancer 14,3:154-161.
Iwamoto S, Takahashi T, Tamagawa H, et al. (2015). FOLFIRI plus bevacizumab as secondline therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus
oxaliplatin-based therapy: the randomized phase III EAGLE study. Annals of Oncology
26,7:1427-1433.
Jalil O, Claydon L and Arulampalam T. (2015). Review of Neoadjuvant Chemotherapy Alone
in Locally Advanced Rectal Cancer. Journal of Gastrointestinal Cancer 46,3:219-236.
Khattak MA, Martin H, Davidson A, et al. (2015). Role of first-line anti-epidermal growth
factor receptor therapy compared with anti-vascular endothelial growth factor therapy in
advanced colorectal cancer: a meta-analysis of randomized clinical trials. Clinical
Colorectal Cancer 14,2:81-90.
Mayer RJ, Van Cutsem E, Falcone A, et al. (2015). Randomized trial of TAS-102 for
refractory metastatic colorectal cancer. New England Journal of Medicine 372,20:1909-1919.
Passardi A, Nanni O, Tassinari D, et al. (2015). Effectiveness of bevacizumab added to
standard chemotherapy in metastatic colorectal cancer: final results for first-line
treatment from the ITACa randomized clinical trial. Annals of Oncology 26,6:1201-1207.
Pectasides D, Karavasilis V, Papaxoinis G, et al. (2015). Randomized phase III clinical trial
comparing the combination of capecitabine and oxaliplatin (CAPOX) with the
combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant
therapy in patients with operated high-risk stage II or stage III colorectal cancer. BMC
Cancer 15,384.
Simkens LH, van Tinteren H, May A, et al. (2015). Maintenance treatment with capecitabine
and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised
controlled trial of the Dutch Colorectal Cancer Group. Lancet 385,9980:1843-1852.
Sohal DP, Rice TW, Rybicki LA, et al. (2015). Gefitinib in definitive management of
esophageal or gastroesophageal junction cancer: a retrospective analysis of two clinical
trials. Diseases of the Esophagus 28,6:547-551.
4
GI Cancers, August 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Tabernero J, Yoshino T, Cohn AL, et al. (2015). Ramucirumab versus placebo in
combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma
that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a
fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet
Oncology 16,5:499-508.
Tanabe K, Fujii M, Nishikawa K, et al. (2015). Phase II/III study of second-line chemotherapy
comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer
refractory to first-line treatment with S-1 (JACCRO GC-05). Annals of Oncology 26,9:19161922.
Pathology, Staging, Polymorphisms & Biomarkers
Basavaraju U, Shebl FM, Palmer AJ, et al. (2015). Cytokine gene polymorphisms, cytokine
levels and the risk of colorectal neoplasia in a screened population of Northeast
Scotland. European Journal of Cancer Prevention 24,4:296-304.
Brosens LA, Offerhaus GJ and Giardiello FM. (2015). Hereditary Colorectal Cancer: Genetics
and Screening. Surgical Clinics of North America 95,5:1067-1080.
Cho, J.W. (2015). The Role of Endosonography in the Staging of Gastrointestinal Cancers.
Clinical Endoscopy 48,4:297-301.
Dickinson BT, Kisiel J, Ahlquist DA, et al. (2015). Molecular markers for colorectal cancer
screening. Gut 64,9:1485-1494.
Garborg, K. (2015). Colorectal Cancer Screening. Surgical Clinics of North America 95,5:979989.
Halligan S, Dadswell E, Wooldrage K, et al. (2015). Computed tomographic colonography
compared with colonoscopy or barium enema for diagnosis of colorectal cancer in older
symptomatic patients: two multicentre randomised trials with economic evaluation (the
SIGGAR trials). Health technology assessment (Winchester, England) 19,54:1-134.
He J and Ahuja N. (2015). Personalized Approaches to Gastrointestinal Cancers:
Importance of Integrating Genomic Information to Guide Therapy. Surgical Clinics of North
America 95,5:1081-1094.
Krebs MG, Renehan AG, Backen A, et al. (2015). Circulating Tumor Cell Enumeration in a
Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. Clinical Colorectal
Cancer 14,2:115-22.e1-2.
Mima K, Sukawa Y, Nishihara R, et al. (2015). Fusobacterium nucleatum and T Cells in
Colorectal Carcinoma. JAMA Oncology 1,5:653-661.
Stoffel, E.M. (2015). Screening in GI Cancers: The Role of Genetics. Journal of Clinical
Oncology 33,16:1721-1728.
van der Post RS, Vogelaar IP, Carneiro F, et al. (2015). Hereditary diffuse gastric cancer:
updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.
Journal of medical genetics 52,6:361-374.
Verberne CJ, Zhan Z, van den Heuvel E, et al. (2015). Intensified follow-up in colorectal
cancer patients using frequent Carcino-Embryonic Antigen (CEA) measurements and
CEA-triggered imaging: Results of the randomized "CEAwatch" trial. European Journal of
Surgical Oncology 41,9:1188-1196.
5
GI Cancers, August 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Prognosis, Survival & Risk Factors
Markar S, Gronnier C, Duhamel A, et al. (2015). Pattern of Postoperative Mortality After
Esophageal Cancer Resection According to Center Volume: Results from a Large
European Multicenter Study. Annals of Surgical Oncology 22,8:2615-2623.
Melis M, Masi A, Pinna A, et al. (2015). Does lymph node ratio affect prognosis in
gastroesophageal cancer?. American Journal of Surgery 210,3:443-450.
Mocellin S and Nitti D. (2015). Lymphadenectomy extent and survival of patients with
gastric carcinoma: a systematic review and meta-analysis of time-to-event data from
randomized trials. Cancer treatment reviews 41,5:448-454.
Petrelli F, Pezzica E, Cabiddu M, et al. (2015). Tumour Budding and Survival in Stage II
Colorectal Cancer: a Systematic Review and Pooled Analysis. Journal of Gastrointestinal
Cancer 46,3:212-218.
Petrelli F, Pietrantonio F, Cremolini C, et al. (2015). Early tumour shrinkage as a prognostic
factor and surrogate end-point in colorectal cancer: a systematic review and pooledanalysis. European journal of cancer 51,7:800-807.
Sehdev A and O'Neil BH. (2015). The Role of Aspirin, Vitamin D, Exercise, Diet, Statins, and
Metformin in the Prevention and Treatment of Colorectal Cancer. Current Treatment
Options in Oncology 16,9:359.
van Hoeve JC, Elferink MA, Klaase JM, et al. (2015). Long-term effects of a regional care
pathway for patients with rectal cancer. International journal of colorectal disease 30,6:787795.
van't Sant HP, Kamman A, Hop WC, et al. (2015). The influence of mechanical bowel
preparation on long-term survival in patients surgically treated for colorectal cancer.
American Journal of Surgery 210,1:106-110.
Veen T, Stormark K, Nedrebo BS, et al. (2015). Long-Term Follow-Up and Survivorship
After Completing Systematic Surveillance in Stage I-III Colorectal Cancer: Who Is Still at
Risk?. Journal of Gastrointestinal Cancer 46,3:259-266.
Radiotherapy & Imaging
Bentley-Hibbert S and Schwartz L. (2015). Use of Imaging for GI Cancers. Journal of Clinical
Oncology 33,16:1729-1736.
Brooks C, Hansen VN, Riddell A, et al. (2015). Proposed genitalia contouring guidelines in
anal cancer intensity-modulated radiotherapy. British Journal of Radiology
88,1051:20150032.
Daroui P, Jabbour SK, Herman JM, et al. (2015). ACR Appropriateness Criteria Resectable
Stomach Cancer. Oncology (Williston Park) 29,8:
Gauthe M, Richard-Molard M, Cacheux W, et al. (2015). Role of fluorine 18
fluorodeoxyglucose positron emission tomography/computed tomography in
gastrointestinal cancers. Digestive & Liver Disease 47,6:443-454.
6
GI Cancers, August 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Goense L, van Rossum PS, Reitsma JB, et al. (2015). Diagnostic Performance of 18F-FDG
PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with
Curative Intent: A Systematic Review and Meta-Analysis. Journal of Nuclear Medicine
56,7:995-1002.
Hajj C and Goodman KA. (2015). Role of Radiotherapy and Newer Techniques in the
Treatment of GI Cancers. Journal of Clinical Oncology 33,16:1737-1744.
Huang Z, Xie DH, Guo L, et al. (2015). The utility of MRI for pre-operative T and N staging of
gastric carcinoma: a systematic review and meta-analysis. British Journal of Radiology
88,1050:20140552.
Maffione AM, Marzola MC, Capirci C, et al. (2015). Value of (18)F-FDG PET for Predicting
Response to Neoadjuvant Therapy in Rectal Cancer: Systematic Review and MetaAnalysis. AJR.American Journal of Roentgenology 204,6:1261-1268.
Memon S, Lynch AC, Bressel M, et al. (2015). Systematic review and meta-analysis of the
accuracy of MRI and endorectal ultrasound in the restaging and response assessment of
rectal cancer following neoadjuvant therapy. Colorectal Disease 17,9:748-761.
Pettersson D, Lorinc E, Holm T, et al. (2015). Tumour regression in the randomized
Stockholm III Trial of radiotherapy regimens for rectal cancer. British Journal of Surgery
102,8:972-978.
Wiltink LM, Nout RA, Fiocco M, et al. (2015). No Increased Risk of Second Cancer After
Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized
TME, PORTEC-1, and PORTEC-2 Trials. Journal of Clinical Oncology 33,15:1640-1646.
Wu AJ, Bosch WR, Chang DT, et al. (2015). Expert Consensus Contouring Guidelines for
Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction
Cancer. International journal of radiation oncology, biology, physics 92,4:911-920.
Supportive Care & Symptom Management
Barret M, Beye B, Leblanc S, et al. (2015). Systematic review: the prevention of
oesophageal stricture after endoscopic resection. Alimentary Pharmacology & Therapeutics
42,1:20-39.
Chen TY, Wiltink LM, Nout RA, et al. (2015). Bowel function 14 years after preoperative
short-course radiotherapy and total mesorectal excision for rectal cancer: report of a
multicenter randomized trial. Clinical Colorectal Cancer 14,2:106-114.
Cheville AL, Alberts SR, Rummans TA, et al. (2015). Improving Adherence to Cancer
Treatment by Addressing Quality of Life in Patients With Advanced Gastrointestinal
Cancers. Journal of Pain & Symptom Management 50,3:321-327.
Currow DC, Quinn S, Agar M, et al. (2015). Double-blind, placebo-controlled, randomized
trial of octreotide in malignant bowel obstruction. Journal of Pain & Symptom Management
49,5:814-821.
Giandomenico F, Gavaruzzi T, Lotto L, et al. (2015). Quality of life after surgery for rectal
cancer: a systematic review of comparisons with the general population. Expert review of
gastroenterology & hepatology 9,9:1227-1242.
7
GI Cancers, August 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Gilbert A, Ziegler L, Martland M, et al. (2015). Systematic Review of Radiation Therapy
Toxicity Reporting in Randomized Controlled Trials of Rectal Cancer: A Comparison of
Patient-Reported Outcomes and Clinician Toxicity Reporting. International journal of
radiation oncology, biology, physics 92,3:555-567.
Jehn CF, Kupferling S, Oskay-Ozcelik G, et al. (2015). A survey of treatment approaches of
malignant ascites in Germany and Austria. Supportive Care in Cancer 23,7:2073-2078.
Lithner M, Klefsgard R, Johansson J, et al. (2015). The significance of information after
discharge for colorectal cancer surgery-a qualitative study. BMC Nursing 14,36.
Malmstrom M, Klefsgard R, Ivarsson B, et al. (2015). Quality of life measurements as an
indicator for timing of support after oesophagectomy for cancer: a prospective study.
BMC Health Services Research 15,96.
Naghibi M, Smith TR and Elia M. (2015). A systematic review with meta-analysis of survival,
quality of life and cost-effectiveness of home parenteral nutrition in patients with
inoperable malignant bowel obstruction. Clinical Nutrition 34,5:825-837.
Nishimura J, Satoh T, Fukunaga M, et al. (2015). Combination antiemetic therapy with
aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based
chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. European
journal of cancer 51,10:1274-1282.
Park JH, Lee J, Oh M, et al. (2015). The effect of oncologists' exercise recommendations
on the level of exercise and quality of life in survivors of breast and colorectal cancer: A
randomized controlled trial. Cancer 121,16:2740-2748.
Philips P, North DA, Scoggins C, et al. (2015). Gastric-Esophageal Stenting for Malignant
Dysphagia: Results of Prospective Clinical Trial Evaluation of Long-Term
Gastroesophageal Reflux and Quality of Life-Related Symptoms. Journal of the American
College of Surgeons 221,1:165-173.
Song GM, Tian X, Zhang L, et al. (2015). Immunonutrition Support for Patients Undergoing
Surgery for Gastrointestinal Malignancy: Preoperative, Postoperative, or Perioperative?
A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Medicine
94,29:e1225.
Stead M, Craigie AM, Macleod M, et al. (2015). Why are some people more successful at
lifestyle change than others? Factors associated with successful weight loss in the
BeWEL randomised controlled trial of adults at risk of colorectal cancer. International
Journal of Behavioral Nutrition & Physical Activity 12,87.
Sun V, Kim J, Kim JY, et al. (2015). Dietary alterations and restrictions following surgery
for upper gastrointestinal cancers: Key components of a health-related quality of life
intervention. European Journal of Oncology Nursing 19,4:343-348.
van der Heide I, Uiters E, Jantine Schuit A, et al. (2015). Health literacy and informed
decision making regarding colorectal cancer screening: a systematic review. European
journal of public health 25,4:575-582.
Yamana I, Takeno S, Hashimoto T, et al. (2015). Randomized Controlled Study to Evaluate
the Efficacy of a Preoperative Respiratory Rehabilitation Program to Prevent
Postoperative Pulmonary Complications after Esophagectomy. Digestive surgery 32,5:331337.
8
GI Cancers, August 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Surgery
Aurello P, Magistri P, D'Angelo F, et al. (2015). Treatment of esophagojejunal anastomosis
leakage: a systematic review from the last two decades. American Surgeon 81,5:450-453.
Beamish AJ, Chan DS, Blake PA, et al. (2015). Systematic review and meta-analysis of
enhanced recovery programmes in gastric cancer surgery. International Journal Of Surgery
19,46-54.
Clancy C, O'Leary DP, Burke JP, et al. (2015). A meta-analysis to determine the oncological
implications of conversion in laparoscopic colorectal cancer surgery. Colorectal Disease
17,6:482-490.
Gemmill EH, Humes DJ and Catton JA. (2015). Systematic review of enhanced recovery
after gastro-oesophageal cancer surgery. Annals of the Royal College of Surgeons of
England 97,3:173-179.
Hafner S, Zolk K, Radaelli F, et al. (2015). Water infusion versus air insufflation for
colonoscopy. Cochrane Database of Systematic Reviews 5,009863.
Hirao M, Kurokawa Y, Fujita J, et al. (2015). Long-term outcomes after prophylactic
bursectomy in patients with resectable gastric cancer: Final analysis of a multicenter
randomized controlled trial. Surgery 157,6:1099-1105.
Honda M, Hiki N, Nunobe S, et al. (2015). Preoperative vs Postoperative Eradication of
Helicobacter pylori in 150 Patients with Gastric Cancer: A Randomized Controlled Trial.
Journal of the American College of Surgeons 221,2:273-279.
Huscher CG, Bretagnol F and Corcione F. (2015). Laparoscopic Colorectal Cancer
Resection in High-Volume Surgical Centers: Long-Term Outcomes from the LAPCOLON
Group Trial. World journal of surgery 39,8:2045-2051.
Huttner FJ, Tenckhoff S, Jensen K, et al. (2015). Meta-analysis of reconstruction techniques
after low anterior resection for rectal cancer. British Journal of Surgery 102,7:735-745.
Jiang JB, Jiang K, Dai Y, et al. (2015). Laparoscopic Versus Open Surgery for Mid-Low
Rectal Cancer: a Systematic Review and Meta-Analysis on Short- and Long-Term
Outcomes. Journal of Gastrointestinal Surgery 19,8:1497-1512.
Jiang JB, Jiang K, Wang JJ, et al. (2015). Short-term and Long-term Outcomes Regarding
Laparoscopic Versus Open Surgery for Low Rectal Cancer: A Systematic Review and
Meta-Analysis. Surgical laparoscopy, endoscopy & percutaneous techniques 25,4:286-296.
Lacy AM, Tasende MM, Delgado S, et al. (2015). Transanal Total Mesorectal Excision for
Rectal Cancer: Outcomes after 140 Patients. Journal of the American College of Surgeons
221,2:415-423.
Loggie BW and Thomas P. (2015). Gastrointestinal Cancers With Peritoneal
Carcinomatosis: Surgery and Hyperthermic Intraperitoneal Chemotherapy. Oncology
(Williston Park) 29,7:515-521.
Matsuda A, Miyashita M, Matsumoto S, et al. (2015). Isoperistaltic versus antiperistaltic
stapled side-to-side anastomosis for colon cancer surgery: a randomized controlled trial.
Journal of Surgical Research 196,1:107-112.
Midura EF, Hanseman DJ, Hoehn RS, et al. (2015). The effect of surgical approach on shortterm oncologic outcomes in rectal cancer surgery. Surgery 158,2:453-459.
9
GI Cancers, August 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Schietroma M, Pessia B, Carlei F, et al. (2015). Laparoscopic versus open colorectal
surgery for colon cancer: the effect of surgical trauma on the bacterial translocation. A
prospective randomized study. American Journal of Surgery 210,2:263-269.
Schiphorst AH, Verweij NM, Pronk A, et al. (2015). Non-surgical complications after
laparoscopic and open surgery for colorectal cancer - A systematic review of randomised
controlled trials. European Journal of Surgical Oncology 41,9:1118-1127.
Suen MK, Zahid A, Young JM, et al. (2015). How to decide to undertake a randomized,
controlled trial of stent or surgery in colorectal obstruction. Surgery 157,6:1137-1141.
Takahashi H, Okabayashi K, Tsuruta M, et al. (2015). Self-Expanding Metallic Stents Versus
Surgical Intervention as Palliative Therapy for Obstructive Colorectal Cancer: A Metaanalysis. World journal of surgery 39,8:2037-2044.
Wang Z, Chen J, Su K, et al. (2015). Abdominal drainage versus no drainage postgastrectomy for gastric cancer. Cochrane Database of Systematic Reviews 5,008788.
Wilkinson MJ, Fitzgerald JE, Strauss DC, et al. (2015). Surgical treatment of gastrointestinal
stromal tumour of the rectum in the era of imatinib. British Journal of Surgery 102,8:965971.
Please note that the journal articles you are accessing are subject to the terms and conditions
imposed by the publisher, so there will be a limit on the number of articles an individual may
download or print from a single issue of a journal. You can consult your local NHSGGC library with
any queries.
If you have any questions regarding this or any other library services please contact Library staff –
contact details are at the beginning of the bulletin.
Sources used for this bulletin:
OVID MEDLINE, NICE, SIGN, Healthcare Improvement Scotland
10
GI Cancers, August 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network